ASKA Pharmaceutical Holdings Co.,Ltd. (TYO:4886)
Japan · Delayed Price · Currency is JPY 2,160.00
-30.00 (-1.37%)
Nov 13, 2026, 3:30 PM JST
TYO:4886 Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 71,500 | 71,127 | 64,139 | 62,843 | 60,461 | 56,607 | |
Revenue Growth | 6.68% | 10.90% | 2.06% | 3.94% | 6.81% | 2.58% |
Cost of Revenue | 37,538 | 36,982 | 32,803 | 32,178 | 31,876 | 30,255 |
Gross Profit | 33,962 | 34,145 | 31,336 | 30,665 | 28,585 | 26,352 |
Selling, General & Admin | 21,000 | 21,274 | 18,972 | 19,436 | 19,249 | 17,958 |
Research & Development | 7,060 | 7,060 | 7,031 | 4,728 | 4,227 | 3,598 |
Operating Expenses | 28,037 | 28,311 | 26,003 | 24,164 | 23,476 | 21,556 |
Operating Income | 5,925 | 5,834 | 5,333 | 6,501 | 5,109 | 4,796 |
Interest Expense | -206 | -222 | -51 | -40 | -50 | -56 |
Interest & Investment Income | 406 | 391 | 292 | 334 | 338 | 258 |
Earnings From Equity Investments | -368 | -293 | -53 | -41 | - | - |
Currency Exchange Gain (Loss) | -161 | -161 | -123 | -51 | -43 | - |
Other Non Operating Income (Expenses) | 291 | 115 | -184 | -169 | -70 | -75 |
EBT Excluding Unusual Items | 5,887 | 5,664 | 5,214 | 6,534 | 5,284 | 4,923 |
Gain (Loss) on Sale of Investments | 1,230 | 1,230 | 127 | 3,340 | 124 | -1,151 |
Gain (Loss) on Sale of Assets | -96 | - | -106 | -13 | -52 | 9,382 |
Asset Writedown | - | - | -300 | - | - | -5,953 |
Other Unusual Items | 96 | 96 | 1,257 | - | - | -1,038 |
Pretax Income | 7,117 | 6,990 | 6,192 | 9,861 | 5,356 | 6,163 |
Income Tax Expense | 1,753 | 1,366 | 1,091 | 2,316 | 1,118 | 1,873 |
Earnings From Continuing Operations | 5,364 | 5,624 | 5,101 | 7,545 | 4,238 | 4,290 |
Minority Interest in Earnings | -153 | -200 | - | - | - | - |
Net Income | 5,211 | 5,424 | 5,101 | 7,545 | 4,238 | 4,290 |
Net Income to Common | 5,211 | 5,424 | 5,101 | 7,545 | 4,238 | 4,290 |
Net Income Growth | 9.31% | 6.33% | -32.39% | 78.03% | -1.21% | 58.13% |
Shares Outstanding (Basic) | 28 | 28 | 28 | 28 | 28 | 28 |
Shares Outstanding (Diluted) | 28 | 28 | 28 | 28 | 28 | 28 |
Shares Change | 0.29% | 0.13% | 0.12% | 0.26% | -0.46% | 0.06% |
EPS (Basic) | 183.47 | 191.10 | 179.95 | 266.49 | 150.08 | 151.22 |
EPS (Diluted) | 183.47 | 191.10 | 179.95 | 266.49 | 150.08 | 151.22 |
EPS Growth | 9.17% | 6.20% | -32.47% | 77.57% | -0.75% | 58.03% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | 4,764 | 3,754 | -475 | 166 | 2,890 | 2,263 |
Free Cash Flow Per Share | 167.45 | 132.26 | -16.76 | 5.86 | 102.34 | 79.77 |
Dividend Per Share | 65.000 | 60.000 | 55.000 | 40.000 | 16.000 | 15.000 |
Dividend Growth | 14.04% | 9.09% | 37.50% | 150.00% | 6.67% | - |
Gross Margin | - | 48.01% | 48.86% | 48.80% | 47.28% | 46.55% |
Operating Margin | 8.29% | 8.20% | 8.31% | 10.35% | 8.45% | 8.47% |
Profit Margin | 7.29% | 7.63% | 7.95% | 12.01% | 7.01% | 7.58% |
Free Cash Flow Margin | 6.66% | 5.28% | -0.74% | 0.26% | 4.78% | 4.00% |
EBITDA | 9,069 | 8,919 | 7,580 | 9,163 | 8,236 | 7,681 |
EBITDA Margin | - | 12.54% | 11.82% | 14.58% | 13.62% | 13.57% |
D&A For EBITDA | 3,144 | 3,085 | 2,247 | 2,662 | 3,127 | 2,885 |
EBIT | 5,925 | 5,834 | 5,333 | 6,501 | 5,109 | 4,796 |
EBIT Margin | - | 8.20% | 8.31% | 10.35% | 8.45% | 8.47% |
Effective Tax Rate | - | 19.54% | 17.62% | 23.49% | 20.87% | 30.39% |